<DOC>
	<DOCNO>NCT00442936</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety telcagepant ( MK-0974 ) compare approved medication acute migraine . This study conduct `` triple-dummy '' design ; dose study drug , participant receive 3 form study drug ( 2 capsule active and/or placebo 1 tablet active and/or placebo ) instruct take one form study drug dosing time . The primary hypothesis study telcagepant superior placebo Pain Freedom 2 Hours Post-Dose , Pain Relief 2 Hours Post-Dose , Absence Photophobia 2 Hours Post-Dose , Absence Phonophobia 2 Hours Post-Dose Absence Nausea 2 Hours Post-Dose .</brief_summary>
	<brief_title>Study Telcagepant ( MK-0974 ) Participants With Moderate Severe Acute Migraine With Without Aura ( MK-0974-011 )</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<criteria>Has least 1 year history migraine ( without aura ) Females child bear potential must use acceptable contraception throughout trial . Is pregnant/breastfeeding ( female expect conceive study period ) Has history evidence stroke/transient ischemic attack , heart disease , coronary artery vasospasm , significant underlie cardiovascular disease , uncontrolled hypertension ( high blood pressure ) , uncontrolled diabetes , human immunodeficiency virus ( HIV ) disease Has major depression , pain syndrome might interfere study assessment , psychiatric condition , dementia , significant neurological disorder ( migraine ) Has history gastric , small intestinal surgery , disease cause malabsorption Has history cancer within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>